Allarity Therapeutics Inc
Allarity Therapeutics Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of autoimmune and inflammatory diseases, primarily through its lead candidate, ALLN-346, an oral, small molecule inhibitor of the interleukin-17 receptor.
Business. Allarity Therapeutics Inc (ALLR.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Allarity Therapeutics Inc (ALLR.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Allarity Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $14.69 million, which significantly exceeds its total liabilities of $8.43 million, resulting in a current ratio of 2.13. The company's price-to-book ratio of 1.86 suggests that the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible assets are being capitalized.
The company is currently unprofitable, with a net loss of $11.23 million and an operating loss of $12.61 million. Its return on equity is -1.14, and return on assets is -0.62, both significantly below the typical performance metrics for the biotechnology industry. The company's enterprise value to revenue ratio of 15.73 is high, reflecting the market's speculative nature and the early-stage development of its pipeline.
Allarity Therapeutics Inc operates as a single business segment, with no disclosed geographic revenue concentration. The company's operations are primarily focused on the development of its lead candidate, ALLN-346, and there are no material revenue contributions from other segments or regions.
The company's revenue is expected to remain flat in the current fiscal year, with no significant growth anticipated in the next fiscal year. The company is in the early stages of clinical development, and its revenue is not yet derived from product sales. The capital expenditure of $8,000 is minimal, reflecting the company's focus on research and development rather than physical infrastructure.
The company faces low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio of 0.14 indicates a conservative capital structure, and the company's liquidity position is strong. The absence of significant debt and the presence of substantial cash reserves reduce the risk of financial distress.
Recent events include the company's ongoing clinical trials for ALLN-346, which is in Phase 2 development for the treatment of psoriasis. The company has also received a mean price target of $9.75 from analysts, indicating a potential upside from the current market price of $1.185. The company has not issued any recent filings that would suggest a change in its financial or operational strategy.
- Allarity Therapeutics Inc has a strong liquidity position with $14.69 million in cash and equivalents.
- The company is currently unprofitable, with a net loss of $11.23 million and an operating loss of $12.61 million.
- The company's enterprise value to revenue ratio of 15.73 is high, reflecting the market's speculative nature.
- The company operates as a single business segment with no material geographic revenue concentration.
- The company faces low dilution risk and has a conservative capital structure with a debt-to-equity ratio of 0.14.
- Analysts have assigned a mean price target of $9.75, indicating a potential upside from the current market price.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,96 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -14,0M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- See Remarks · Restricted Stock Units → Common StockDisposed 39 494exercise · 2025-09-30
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Allarity Therapeutics Inc Market data — financials · 2026-05-27
- Allarity Therapeutics Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
- CFO · Common StockOther 150 000 · 2026-01-28
- CEO · Common StockOther 200 000 · 2026-01-28
- Director · Common StockOther 45 000 · 2026-01-28
- See Remarks · Common StockOther 133 333 · 2026-01-07
- Director · Common StockOther 25 000 · 2026-01-07
- See Remarks · Common StockOther 39 494 · 2025-09-30
- See Remarks · Common StockOther 14 613 @ $1,58$23K · 2025-09-30
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -24.8%Derived (calculated)
- Return on equity (FY 2025-12-31): -114.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -61.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 54.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.13xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -97.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 95.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.86xDerived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -19.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -22.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 53.7%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 8.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -16.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 14.6%Derived (calculated)
- Total operating expenses (annual): USD 12.93MSEC XBRL filing
- Pre-tax income (annual): USD -11.23MSEC XBRL filing
- Total liabilities (annual): USD 8.43MSEC XBRL filing
- Cash & equivalents (annual): USD 14.69MSEC XBRL filing
- Capex (annual): USD 8KSEC XBRL filing
- Current liabilities (annual): USD 8.43MSEC XBRL filing
- Shares outstanding (annual): 16.08MSEC XBRL filing
- Operating cash flow (annual): USD -14.82MSEC XBRL filing
- Current assets (annual): USD 17.93MSEC XBRL filing
- Shareholders' equity (annual): USD 9.83MSEC XBRL filing